In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana, psychedelics ...
LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...
COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Seven ...
CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, 2025, 8:00 a.m. ET ...
LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced ...
Highlights: 52-week observational follow-up study from Phase 2b reveals single 25 mg COMP360 psilocybin dose offers longer-term antidepressant effects compared to lower doses, with average efficacy ...
In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback